August 27th 2025
NYC officials confirm 113 cases and six deaths in Central Harlem cooling tower–linked outbreak; separate Bronx investigation underway after cases tied to hot water system.
Email Reminders for Influenza Vaccine Uptake May Be Less Effective in Patients with Diabetes
December 21st 2023Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.
Read More
FDA: COVID-19 Moderna Vaccine Dose Needs to be Adjusted for Pediatric Population
November 7th 2023The federal agency was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.
Read More
Understanding Multidrug-Resistant Pathogens (MDR) and Antimicrobial Stewardship in CAP
November 6th 2023An expert in infectious diseases comments on multidrug-resistant pathogens such as pneumococcus in CAP, and shares thoughts on balancing antimicrobial stewardship with the pharmacoeconomics of antimicrobial therapies in CAP.
Watch
Strategies for Approaching Treatment Selection of CAP
October 30th 2023Dr George Sakoulas shares strategies for selecting single and combination therapy when dealing with empiric vs focused treatment regimens for CAP and discusses clinical considerations for elderly patients hospitalized with CAP.
Watch
Moderna Begins Phase 3 Trial for its Influenza-COVID-19 Vaccine
October 26th 2023The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.
Read More
CDC Issues Health Advisory Alert After Increases in RSV Activity
September 6th 2023Due to increased RSV activity in the southeast United States, the CDC has issued an official Health Alert Network Health Advisory. The federal agency recommends clinicians prepare to implement recently FDA-approved prevention methods.
Read More
Counseling Families on Nirsevimab
August 17th 2023With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.
Watch